Ashleigh Scott

To the Editor: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy for myelodysplastic syndromes (MDS) and optimising patients for transplant is critical to achieving the best outcomes [1, 2]. Hypomethylating agents (HMAs), particularly azacitidine, are used as a bridging strategy with the aim of achieving disease control and limiting leukemic transformation.

Introduction Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a potentially fatal complication following haemopoietic stem cell transplantation (HSCT). SOS/VOD can also be observed in patients in the absence of HSCT following toxin exposures and has been described in patients who have received therapies with immunoconjugates such as inotuzumab ozogamicin (InO) and gemtuzumab ozogamicin (GO).